Kufor Rakeb Syndrome (Park9) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Kufor-Rakeb Syndrome (PARK9) | |
|---|---|
| [^7] Brain MRI showing generalized atrophy and basal ganglia iron deposition [^8] | |
| Also Known As | Parkinson Disease 9 (PARK9), Pallido-Pyramidal Syndrome, Juvenile-Onset Parkinsonism with Brain Iron Accumulation |
| ICD-10 | G20.A (Parkinson disease due to genetic cause) |
| OMIM | 606693 |
| Inheritance | Autosomal recessive |
| Gene | ATP13A2, chromosome 1p36.13 |
| Protein | ATP13A2 / PARK9 (lysosomal P5B-type ATPase) |
| Onset | Juvenile (typically 11–16 years) |
| Key Features | Levodopa-responsive parkinsonism, supranuclear gaze palsy, pyramidal signs, dementia, brain iron accumulation |
| Prevalence | Ultra-rare; fewer than 100 families reported worldwide |
Kufor-Rakeb syndrome (KRS), designated PARK9, is an ultra-rare autosomal recessive neurodegenerative disorder representing one of the most aggressive forms of genetic parkinsonism. The disease is caused by biallelic loss-of-function mutations in the ATP13A2 gene, which encodes a lysosomal P5B-type ATPase involved in polyamine transport, metal homeostasis, and lysosomal function.
[1]
KRS was first described in 2001 by Najim al-Din et al. in a consanguineous Jordanian family from the village of Kufor-Rakeb, near Irbid. The affected individuals presented with juvenile-onset parkinsonism, pyramidal tract dysfunction, supranuclear gaze palsy, and dementia — a combination that distinguished this syndrome from other juvenile parkinsonism forms. The causative gene was mapped in 2001 and identified as ATP13A2 in 2006 by Ramirez et al.
[2]
KRS occupies a unique position at the intersection of Mendelian parkinsonism, neurodegeneration with brain iron accumulation (NBIA), and lysosomal storage disorders. Brain MRI often reveals iron deposition in the putamen and caudate nucleus alongside generalized cerebral atrophy, linking KRS pathogenetically to the NBIA spectrum. The disease typically manifests in adolescence and progresses rapidly, with patients often dying by the third decade of life.
[3]
Kufor-Rakeb syndrome is one of the rarest forms of genetic parkinsonism, with fewer than 100 families reported worldwide since its initial description. Cases have been identified across diverse ethnic groups, including families of Jordanian, Chilean, Pakistani, Afghan, Japanese, Italian, Brazilian, and European descent. The true prevalence is unknown but likely underestimated due to diagnostic challenges and overlap with other juvenile parkinsonism forms.
[4]
The disease shows no sex predilection. Onset typically occurs in the second decade of life, with a median age of onset around 12–16 years. Consanguineous families are overrepresented due to the autosomal recessive inheritance pattern.
[2:1]
ATP13A2 is located on chromosome 1p36.13 and encodes a 1180-amino acid transmembrane protein with 10 transmembrane domains. ATP13A2 belongs to the P5B subgroup of P-type ATPases and is primarily localized to the lysosomal and late endosomal membrane, with additional expression at the endoplasmic reticulum.[5]
Over 30 pathogenic mutations have been identified, including missense, nonsense, splice-site, and frameshift variants. Most mutations result in misfolded protein that is retained in the ER and degraded by the proteasome, leading to effective loss of function at the lysosomal membrane.
[^6]
The primary biochemical function of ATP13A2 is the ATP-dependent transport of polyamines — spermine and spermidine — from the lysosomal lumen to the cytosol. Structural studies have revealed the conformational cycle of ATP13A2 during polyamine transport, showing how it couples ATP hydrolysis to substrate translocation across the lysosomal membrane.
[^7]
Loss of ATP13A2 function leads to:
ATP13A2 plays important roles in intracellular metal homeostasis:
ATP13A2 deficiency triggers multiple interconnected neurodegenerative cascades:
The motor presentation of KRS combines features of both parkinsonism and pyramidal tract dysfunction:
Cognitive decline is a prominent and progressive feature:
Diagnosis should be suspected in patients presenting with:
The combination of juvenile parkinsonism with supranuclear gaze palsy and pyramidal signs is highly suggestive of KRS.[3:2]
Brain MRI reveals:
CT scan may show caudate and lentiform nucleus atrophy even early in the disease course.[4:2]
Definitive diagnosis requires identification of biallelic pathogenic variants in ATP13A2 through targeted gene sequencing or next-generation sequencing panels for genetic parkinsonism or NBIA. Whole-exome sequencing may be necessary for novel or atypical variants.[^6]
The differential diagnosis of juvenile-onset parkinsonism with additional neurological features includes:
KRS is among the most aggressive forms of genetic parkinsonism. Disease onset typically occurs in early adolescence (ages 11–16), and the condition progresses rapidly with accumulating motor disability, cognitive decline, and loss of independence. Without effective disease-modifying therapy, patients often die in their late 20s to 30s due to complications including aspiration pneumonia, immobility-related complications, and status epilepticus. The rapidly progressive nature of KRS underscores the critical importance of ATP13A2 function for neuronal survival and highlights the urgent need for targeted therapies.
[3:4]
ATP13A2 knockout models have been developed in multiple species:
The study of Kufor Rakeb Syndrome (Park9) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Kufor-Rakeb syndrome: a cohort-based clinical, imaging and genetic profile. ↩︎
Kufor-Rakeb Syndrome in a Guatemalan Patient With an ATP13A2 Gene Pathogenic Variant: A Case Report. ↩︎ ↩︎
Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson's disease. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
C-Myc Indirectly Controls ATP13A2 Levels via HIF-1α Activation. ↩︎ ↩︎ ↩︎ ↩︎
Quantitative Iron Measurements in the Basal Ganglia of NBIA Patients Using QSM: Insights From a Tertiary Center. ↩︎ ↩︎